Organ-protective and immunomodulatory effects of erythropoietin - an update on recent clinical trials

Basic and Clinical Pharmacology and Toxicology

Volumn 110, Issue 2, 2012, Pages 113-121

  Sølling, Christoffer ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; CYTOCHROME C; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL XL; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; RECOMBINANT ERYTHROPOIETIN; STAT3 PROTEIN; STAT5 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; NEUROPROTECTIVE AGENT;

ACUTE HEART INFARCTION; ACUTE KIDNEY FAILURE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; BRAIN BLOOD FLOW; BRAIN METABOLISM; CELL STRESS; CELLULAR IMMUNITY; CHEMICAL STRUCTURE; COGNITIVE DEFECT; CRITICAL ILLNESS; DRUG MEGADOSE; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PROTECTION; HEMATOPOIESIS; HUMAN; IMMUNOMODULATION; INFLAMMATION; INTRACELLULAR SIGNALING; ISCHEMIA; LUNG EMBOLISM; NEOVASCULARIZATION (PATHOLOGY); NEUROPROTECTION; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PLEIOTROPY; PRIORITY JOURNAL; PROTECTION; PROTEIN FUNCTION; PROTEIN STRUCTURE; RENAL PROTECTION; REPERFUSION INJURY; SHORT SURVEY; SINGLE DRUG DOSE; STROKE; THROMBOSIS; UNSPECIFIED SIDE EFFECT; VASOSPASM; WOUND HEALING; ANIMAL; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; METABOLISM; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANIMALIA;

ANIMALS; APOPTOSIS; CRITICAL ILLNESS; DISEASE MODELS, ANIMAL; ERYTHROPOIETIN; HEMATOPOIESIS; HUMANS; IMMUNOMODULATION; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ERYTHROPOIETIN;

EID: 84855939143     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2011.00820.x     Document Type: Short Survey

References (60)

1. Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG. Statins: panacea for sepsis? Lancet Infect Dis 2006;6:242-8.
2. Brix-Christensen V, Andersen SK, Andersen R, Mengel A, Dyhr T, Andersen NT et al. Acute hyperinsulinemia restrains endotoxin-induced systemic inflammatory response: an experimental study in a porcine model. Anesthesiology 2004;100:861-70.
3. Becher UM, Endtmann C, Tiyerili V, Nickenig G, Werner N. Endothelial damage and regeneration: the role of the renin-angiotensin-aldosterone system. Curr Hypertens Rep 2011;13:86-92.
4. Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood) 2003;228:1-14.
5. Jelkmann W. Erythropoietin after a century of research: younger than ever. Eur J Haematol 2007;78:183-205.
6. Jelkmann W. Molecular biology of erythropoietin. Intern Med 2004;43:649-59.
7. Takeuchi M, Kobata A. Structures and functional roles of the sugar chains of human erythropoietins. Glycobiology 1991;1:337-46.
8. Mocini D, Leone T, Tubaro M, Santini M, Penco M. Structure, production and function of erythropoietin: implications for therapeutical use in cardiovascular disease. Curr Med Chem 2007;14:2278-87.
9. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA 2005;293:90-5.
10. Jelkmann W, Bohlius J, Hallek M, Sytkowski AJ. The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol 2008;67:39-61.
11. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 2001;412:641-7.
12. Lundby C, Thomsen JJ, Boushel R, Koskolou M, Warberg J, Calbet JA et al. Erythropoietin treatment elevates haemoglobin concentration by increasing red cell volume and depressing plasma volume. J Physiol 2007;578:309-14.
13. Yu X, Shacka JJ, Eells JB, Suarez-Quian C, Przygodzki RM, Beleslin-Cokic B et al. Erythropoietin receptor signalling is required for normal brain development. Development 2002;129:505-16.
14. Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol 2008;141:14-31.
15. Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA 2004;101:14907-12.
16. Brines M, Cerami A. Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med 2008;264:405-32.
17. Sinclair AM, Coxon A, McCaffery I, Kaufman S, Paweletz K, Liu L et al. Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood 2010;115:4264-72.
18. Mazur M, Miller RH, Robinson S. Postnatal erythropoietin treatment mitigates neural cell loss after systemic prenatal hypoxic-ischemic injury. J Neurosurg Pediatr 2010;6:206-21.
19. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 2003;100:4802-6.
20. Sepodes B, Maio R, Pinto R, Sharples E, Oliveira P, McDonald M et al. Recombinant human erythropoietin protects the liver from hepatic ischemia-reperfusion injury in the rat. Transpl Int 2006;19:919-26.
21. Wu H, Ren B, Zhu J, Dong G, Xu B, Wang C et al. Pretreatment with recombined human erythropoietin attenuates ischemia-reperfusion-induced lung injury in rats. Eur J Cardiothorac Surg 2006;29:902-7.
22. Solling C, Christensen AT, Krag S, Froki AE Jr, Wogensen L, Krog J et al. Erythropoietin administration is associated with short-term improvement in glomerular filtration rate after ischemia-reperfusion injury. Acta Anaesthesiol Scand 2011;55:185-95.
23. Mitra A, Bansal S, Wang W, Falk S, Zolty E, Schrier RW. Erythropoietin ameliorates renal dysfunction during endotoxaemia. Nephrol Dial Transplant 2007;22:2349-53.
24. Cuzzocrea S, Di PR, Mazzon E, Patel NS, Genovese T, Muia C et al. Erythropoietin reduces the development of nonseptic shock induced by zymosan in mice. Crit Care Med 2006;34:1168-77.
25. Aoshiba K, Onizawa S, Tsuji T, Nagai A. Therapeutic effects of erythropoietin in murine models of endotoxin shock. Crit Care Med 2009;37:889-98.
26. Solling C, Christensen AT, Nygaard U, Krag S, Froki AE Jr, Wogensen L et al. Erythropoietin does not attenuate renal dysfunction or inflammation in a porcine model of endotoxemia. Acta Anaesthesiol Scand 2011;55:411-21.
27. Abdelrahman M, Sharples EJ, McDonald MC, Collin M, Patel NS, Yaqoob MM et al. Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock 2004;22:63-9.
28. Wu WT, Hu TM, Lin NT, Subeq YM, Lee RP, Hsu BG. Low-dose erythropoietin aggravates endotoxin-induced organ damage in conscious rats. Cytokine 2009;49:155-62.
29. Corwin HL, Gettinger A, Fabian TC, May A, Pearl RG, Heard S et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007;357:965-76.
30. Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Shapiro MJ et al. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA 2002;288:2827-35.
31. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002;8:495-505.
32. Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 2009;40:e647-56.
33. Ehrenreich H, Kastner A, Weissenborn K, Streeter J, Sperling S, Wang KK et al. Circulating damage marker profiles support a neuroprotective effect of erythropoietin in ischemic stroke patients. Mol Med 2011; [Epub ahead of print].
34. Springborg JB, Moller C, Gideon P, Jorgensen OS, Juhler M, Olsen NV. Erythropoietin in patients with aneurysmal subarachnoid haemorrhage: a double blind randomised clinical trial. Acta Neurochir (Wien) 2007;149:1089-101.
35. Tseng MY, Hutchinson PJ, Richards HK, Czosnyka M, Pickard JD, Erber WN et al. Acute systemic erythropoietin therapy to reduce delayed ischemic deficits following aneurysmal subarachnoid hemorrhage: a phase II randomized, double-blind, placebo-controlled trial. Clinical article. J Neurosurg 2009;111:171-80.
36. Haljan G, Maitland A, Buchan A, Arora RC, King M, Haigh J et al. The erythropoietin neuroprotective effect: assessment in CABG surgery (TENPEAKS): a randomized, double-blind, placebo controlled, proof-of-concept clinical trial. Stroke 2009;40:2769-75.
37. Voors AA, Belonje AM, Zijlstra F, Hillege HL, Anker SD, Slart RH et al. A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J 2010;31:2593-2600.
38. Ferrario M, Arbustini E, Massa M, Rosti V, Marziliano N, Raineri C et al. High-dose erythropoietin in patients with acute myocardial infarction: a pilot, randomised, placebo-controlled study. Int J Cardiol 2011;147:124-31.
39. Ott I, Schulz S, Mehilli J, Fichtner S, Hadamitzky M, Hoppe K et al. Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial. Circ Cardiovasc Interv 2010;3:408-13.
40. Najjar SS, Rao SV, Melloni C, Raman SV, Povsic TJ, Melton L et al. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA 2011;305:1863-72.
41. Ludman AJ, Yellon DM, Hasleton J, Ariti C, Babu GG, Boston-Griffiths E et al. Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trial. Heart 2011;97:1560-5.
42. Joyeux-Faure M, Durand M, Bedague D, Protar D, Incagnoli P, Paris A et al. Evaluation of the effect of one large dose of erythropoietin against cardiac and cerebral ischemic injury occurring during cardiac surgery with cardiopulmonary bypass: a randomized double-blind placebo-controlled pilot study. Fundam Clin Pharmacol 2011; [Epub ahead of print].
43. Poulsen TD, Andersen LW, Steinbruchel D, Gotze JP, Jorgensen OS, Olsen NV. Two large preoperative doses of erythropoietin do not reduce the systemic inflammatory response to cardiac surgery. J Cardiothorac Vasc Anesth 2009;23:316-23.
44. Hojman P, Taudorf S, Lundby C, Pedersen BK. Erythropoietin augments the cytokine response to acute endotoxin-induced inflammation in humans. Cytokine 2009;45:154-7.
45. Song YR, Lee T, You SJ, Chin HJ, Chae DW, Lim C et al. Prevention of acute kidney injury by erythropoietin in patients undergoing coronary artery bypass grafting: a pilot study. Am J Nephrol 2009;30:253-60.
46. Endre ZH, Walker RJ, Pickering JW, Shaw GM, Frampton CM, Henderson SJ et al. Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int 2010;77:1020-30.
47. Martinez F, Kamar N, Pallet N, Lang P, Durrbach A, Lebranchu Y et al. High dose epoetin beta in the first weeks following renal transplantation and delayed graft function: results of the Neo-PDGF Study. Am J Transplant 2010;10:1695-700.
48. Stohlawetz PJ, Dzirlo L, Hergovich N, Lackner E, Mensik C, Eichler HG et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 2000;95:2983-9.
49. Macdougall IC, Davies ME, Hallett I, Cochlin DL, Hutton RD, Coles GA et al. Coagulation studies and fistula blood flow during erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant 1991;6:862-7.
50. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-98.
51. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009;373:1532-42.
52. Spivak JL, Gascon P, Ludwig H. Anemia management in oncology and hematology. Oncologist 2009;14(Suppl. 1):43-56.
53. Goldsmith D. 2009: a requiem for rHuEPOs - but should we nail down the coffin in 2010? Clin J Am Soc Nephrol 2010;5:929-35.
54. Simon F, Scheuerle A, Calzia E, Bassi G, Oter S, Duy CN et al. Erythropoietin during porcine aortic balloon occlusion-induced ischemia/reperfusion injury. Crit Care Med 2008;36:2143-50.
55. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004;305:239-42.
56. Lipsic E, van der MP, Voors AA, Westenbrink BD, van den Heuvel AF, de Boer HC et al. A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther 2006;20:135-41.
57. Mocini D, Muso P, Guendouz E, De ML, Mele L, Cini R et al. Endogenous erythropoietin and a single bolus of 40, 000IU of epoetin alpha do not protect the heart from ischaemia-reperfusion injury during extracorporeal circulation for cardiac surgery. Perfusion 2008;23:187-92.
58. Ozawa T, Toba K, Suzuki H, Kato K, Iso Y, Akutsu Y et al. Single-dose intravenous administration of recombinant human erythropoietin is a promising treatment for patients with acute myocardial infarction - randomized controlled pilot trial of EPO/AMI-1 study. Circ J 2010;74:1415-23.
59. Taniguchi N, Nakamura T, Sawada T, Matsubara K, Furukawa K, Hadase M et al. Erythropoietin prevention trial of coronary restenosis and cardiac remodeling after ST-elevated acute myocardial infarction (EPOC-AMI): a pilot, randomized, placebo-controlled study. Circ J 2010;74:2365-71.
60. Suh JW, Chung WY, Kim YS, Kim KI, Jeon EJ, Cho YS et al. The effect of intravenous administration of erythropoietin on the infarct size in primary percutaneous coronary intervention. Int J Cardiol 2011;149:216-20.